Bellus Health, Pharmascience deal

Generics company Pharmascience will pay C$17.3 million ($17.4 million) to recapitalize Bellus Health into a new public company. Pharmascience will provide

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE